Please login to the form below

Not currently logged in
Email:
Password:

filibuvir

This page shows the latest filibuvir news and features for those working in and with pharma, biotech and healthcare.

AbbVie gets 'breakthrough' status for hepatitis C regimen

AbbVie gets 'breakthrough' status for hepatitis C regimen

In March Pfizer dropped HCV candidate filibuvir after a strategic review of its pipeline, while last year BMS abandoned its polymerase inhibitor BMS-986094 candidate after a patient death in trials.

Latest news

  • Pfizer drops hepatitis C candidate filibuvir Pfizer drops hepatitis C candidate filibuvir

    Pfizer drops hepatitis C candidate filibuvir. Compound was lagging behind investigational drugs from Gilead and AbbVie. ... The decision to drop filibuvir, reported by the Wall Street Journal on Friday, effectively means that Pfizer has withdrawn from

  • HCV hope on the horizon

    Tibotec). Among the polymerase inhibitors, the most advanced in development is Pfizer's non-nucleoside compound filibuvir at phase II.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics